Fast Track status for 4P004 signals a push to accelerate knee osteoarthritis treatment beyond symptom relief toward disease modification.
For something that affects hundreds of millions of people, especially older people, knee osteoarthritis has been treated with surprising resignation, where they manage the pain, delay the damage and, eventually, consider surgery.
That script may be starting to crack. 4Moving Biotech, a France-based clinical-stage company, has secured Fast Track Designation from the US Food and Drug Administration (FDA) for its experimental drug, 4P004 – a move that could accelerate how quickly it reaches patients who have run out of options [1].
The designation signals that regulators see both urgency and potential: urgency in the scale of suffering and potential in a drug that’s trying to do something the field has struggled with for decades – change the disease itself.
To understand why this matters, it helps to look at how osteoarthritis is usually treated. Most therapies today act like temporary fixes; think of them as turning down the volume on pain without fixing the broken speaker. Anti-inflammatories, steroids, even some injections can ease discomfort, but they don’t stop the joint from deteriorating.
4P004 is attempting a different approach. The drug is injected directly into the knee, targeting the joint where damage is happening. It’s built from a GLP-1 analog, a type of compound better known for its role in diabetes and weight management, but repurposed here to act locally on joint tissues.
Instead of doing just one job, it’s designed to work on several fronts at once: reduce inflammation, ease pain, slow down tissue breakdown and potentially support repair. In a disease that affects cartilage, bone and the surrounding environment all at once, that multi-pronged approach could be key.
If it works, 4P004 could become what researchers call a disease-modifying osteoarthritis drug, or DMOAD, a category that has long been more ambition than reality.
The Fast Track designation changes the tempo. Drug development is usually a slow, methodical process. The designation can tighten the timeline. With this, 4Moving Biotech gets more frequent and structured communication with the FDA, helping align on study design, endpoints and next moves. It also opens the possibility of accelerated approval pathways or earlier patient access programs, depending on how the data evolves.
“Fast Track Designation represents a meaningful regulatory milestone for the 4P004 program,” said Luc Boblet, CEO of 4Moving Biotech. “It reflects the significant unmet medical need in knee osteoarthritis and provides a structured framework for enhanced dialogue with the FDA as we prepare the next stages of development.”
In practical terms, that “dialogue” can shave off years of uncertainty, something that matters when patients are living with daily pain and shrinking mobility.
Osteoarthritis affects around 374 million people globally, making it one of the most common (and most overlooked) drivers of disability. And yet, innovation has lagged.
“Current pharmacological treatments for knee osteoarthritis provide limited and often transient relief,” said Prof. Francis Berenbaum, Chief Medical Officer of 4Moving Biotech. “4P004 has been designed to address both symptoms and underlying disease mechanisms in patients with limited therapeutic options.”
“Underlying disease mechanisms” carry the real shift because osteoarthritis isn’t just wear and tear; it’s an active, biological process involving inflammation, tissue breakdown and failed repair. Treating it as such could change the trajectory of the disease, not just the experience of it.
The Fast Track milestone comes on the heels of fresh funding. Earlier this year, 4Moving Biotech raised ~$13 million (€12 million), bringing its total funding to around ~$32 million (€30 million) – enough to push its lead program through a critical proof-of-concept stage [2].
Its ongoing Phase 2a trial, known as INFLAM MOTION, is currently running across Europe and North America, with topline results expected in early 2027. The study is designed not only to measure whether patients feel better, but also whether the drug is influencing the biological processes driving the disease. Feeling better is important, but changing what’s happening beneath the surface is what could redefine treatment.
At its core, it’s also a story about time, how we age, how we move through the world and how long we can maintain independence. Mobility is one of the clearest predictors of healthy aging. Once it declines, everything else tends to follow: physical activity drops, social engagement narrows and the risks of other chronic conditions begin to climb.
When a drug like 4P004 aims to preserve joint function, it’s pushing back against a cascade of age-related decline. That’s what makes this moment worth watching.
The results from INFLAM MOTION will ultimately decide whether 4P004 can deliver on its promise. For now, the FDA’s decision has sped up the clock. For millions living with knee osteoarthritis, time is exactly what’s at stake.
Photograph courtesy of 4Moving Biotech. Main photo shows (L–R): Francis Berenbaum (CMO), Luc Boblet (CEO), Revital Rattenbach (President) and Jérôme Vailland (CFO)
[1] https://www.4movingbiotech.com/2026/04/22/4moving-biotech-granted-fda-fast-track-designation-to-4p004-supporting-an-accelerated-development-pathway-in-knee-osteoarthritis/
[2] https://www.4movingbiotech.com/2026/02/10/knee-osteoarthritis/
